This study is testing a new treatment for people living with HIV. It involves a vaccine called 426c.Mod.Core-C4b, which is combined with a substance to help the body make antibodies, called 3M-052-AF + aluminum hydroxide (Alum). The goal is to see if the vaccine can help the immune system fight the HIV virus better by producing special antibodies known as VRC01-class antibodies. These antibodies are important because they can block many different types of HIV.

Participants need to be 18-55 years old, have controlled HIV with medication, and be in good health. They will need to visit the clinic for regular check-ups and agree to follow certain guidelines about medication and lifestyle during the study.

• The study lasts up to 64 weeks, with regular clinic visits.
• Participants will be monitored for safety and any effects of the vaccine.
• It's important to use effective birth control methods during the study.

Before joining, consider if you can meet the study requirements and are comfortable with the time commitment. This study offers a chance to contribute to HIV research but involves certain risks and responsibilities.